AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

NextEdge Admin

20 Dec 2024

2 min 37 sec

Precision Oncology,liquid biopsies,AI,big data

Caris Life Sciences®, a leading AI-driven TechBio company in precision medicine, has published over 1,000 peer-reviewed studies, posters, and abstracts since 2015, marking a significant milestone in advancing cancer research. In 2024 alone, Caris collaborated with leading cancer centers, including the Caris Precision Oncology Alliance™ (Caris POA), to publish over 70 peer-reviewed studies and 120 abstracts.

"Reaching this milestone underscores our commitment to advancing cancer biology through collaborative efforts," said Caris President David Spetzler, MS, PhD, MBA. "This achievement reflects the combined expertise of clinicians, tumor biologists, and data scientists within the Caris POA."

Key 2024 publications include:

Nature Cancer: Defining tissue-specific TMB thresholds for anti-PD-1/L1 therapy in microsatellite-stable cancers, based on WES and clinical data from 70,000 patients.
Cancer Cell: Demonstrating cancer type-specific immune markers in relation to TMB and anti-PD-1 outcomes, highlighting the need for multiomic approaches.
JCO Precision Oncology: High concordance of NGS-MSI and IHC-MMR in 190,000 patients, revealing complementary insights.
European Urology: Predictive value of ATM, RB1, and ERCC2 mutations in muscle-invasive bladder cancer response to chemotherapy.
Journal of Clinical Investigation: Distinct transcriptional profiles in renal cell carcinoma histologic subtypes, guiding histology-specific treatments.
Clinical Cancer Research: Transcriptional subtypes in pancreatic cancer, predicting outcomes in 8,000 patients.

Caris’ groundbreaking work in molecular profiling for tissue and liquid biopsies and biomarker-driven research reinforces its role as a leader in precision oncology. Leveraging WES, WTS, AI, and big data, Caris delivers innovative solutions for early detection, diagnosis, therapy selection, and drug development, driving better outcomes for cancer patients worldwide.